ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Cancer Education: NCI Offers Training In Epidemiology And Genetics

April 17, 1998

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997

Radiation Exposure Mostly Natural, NCRP Report Says

November 27, 1987

Bush To Propose Increase for Cancer Screening, FDA Generics Reviews

January 31, 2003

In Brief: GM awards Shared By Six Scientists; Pollard Named President of Salk Institute

June 21, 1996

Taking Tykerb With Food Increased Drug Concentration; Paper Urges More Research

July 27, 2007